Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

PURPOSE: Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of I...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:J Clin Oncol
Główni autorzy: Fayad, Luis, Offner, Fritz, Smith, Mitchell R., Verhoef, Gregor, Johnson, Peter, Kaufman, Jonathan L., Rohatiner, Ama, Advani, Anjali, Foran, James, Hess, Georg, Coiffier, Bertrand, Czuczman, Myron, Giné, Eva, Durrant, Simon, Kneissl, Michelle, Luu, Kenneth T., Hua, Steven Y., Boni, Joseph, Vandendries, Erik, Dang, Nam H.
Format: Artigo
Język:Inglês
Wydane: American Society of Clinical Oncology 2013
Hasła przedmiotowe:
ORIGINAL REPORTS
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878046/
https://ncbi.nlm.nih.gov/pubmed/23295790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.7211
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy